Trial · NCT03120949
Results by group690
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 690
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations | 401 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations | 408 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Nasopharyngitis | 71 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Nasopharyngitis | 87 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Upper respiratory tract infection | 59 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Upper respiratory tract infection | 67 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Infections and infestations: Bronchitis | 59 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Infections and infestations: Bronchitis | 45 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Investigations | 284 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Investigations | 290 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Investigations: Alanine aminotransferase increased | 97 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Investigations: Alanine aminotransferase increased | 118 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Investigations: Aspartate aminotransferase increased | 52 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Investigations: Aspartate aminotransferase increased | 63 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Musculoskeletal and connective tissue disorders | 149 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Musculoskeletal and connective tissue disorders | 152 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Blood and lymphatic system disorders | 125 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Blood and lymphatic system disorders | 147 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Blood and lymphatic system disorders: Leukopenia | 46 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Blood and lymphatic system disorders: Leukopenia | 60 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03120949/results